Improved Patient and Primary Renal Allograft Survival in Uremic Diabetic Recipients

Sutherland, David E.R.; Morrow, Charles E.; Fryd, David S.; Ferguson, RonaldM.; Simmons, Richard L.; Najarían, John S.

doi:10.1016/s0022-5347(17)51045-9

Cited by 8 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 However, because of the initially high complication rate with pancreaticoduodenal transplants, this concept was challenged internally. 21 A series of kidney transplants alone (KTA) from living or cadaver donors was initiated in uremic diabetic patients, as reported to the American Surgical Association, 22,23 ultimately producing a large number of candidates 24 for pancreas after kidney (PAK) transplants in era 1. 4 Lillehei switched to doing PTA in nonuremic diabetic patients but had only three cases, and all grafts were rejected within 3 months.…”

Section: Description Of Eras Eramentioning

confidence: 99%

Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution

Sutherland¹,

Gruessner²,

Dünn³

et al. 2001

Annals of Surgery

611

434

View full text Add to dashboard Cite

ObjectiveTo determine outcome in diabetic pancreas transplant recipients according to risk factors and the surgical techniques and immunosuppressive protocols that evolved during a 33-year period at a single institution. Summary Background DataInsulin-dependent diabetes mellitus is associated with a high incidence of management problems and secondary complications. Clinical pancreas transplantation began at the University of Minnesota in 1966, initially with a high failure rate, but outcome improved in parallel with other organ transplants. The authors retrospectively analyzed the factors associated with the increased success rate of pancreas transplants. MethodsFrom December 16, 1966, to March 31, 2000, the authors performed 1,194 pancreas transplants (111 from living donors; 191 retransplants): 498 simultaneous pancreas-kidney (SPK) and 1 simultaneous pancreas-liver transplant; 404 pancreas after kidney (PAK) transplants; and 291 pancreas transplants alone (PTA). The analyses were divided into five eras: era 0, 1966 to 1973 (n ϭ 14), historical; era 1, 1978 to 1986 (n ϭ 148), transition to cyclosporine for immunosuppression, multiple duct management techniques, and only solitary (PAK and PTA) transplants; era 2, 1986 to 1994 (n ϭ 461), all categories (SPK, PAK, and PTA), predominately bladder drainage for graft duct management, and primarily triple therapy (cyclosporine, azathioprine, and prednisone) for maintenance immunosuppression; era 3, 1994 to 1998 (n ϭ 286), tacrolimus and mycophenolate mofetil used; and era 4, 1998 to 2000 (n ϭ 275), use of daclizumab for induction immunosuppression, primarily enteric drainage for SPK transplants, pretransplant immunosuppression in candidates awaiting PTA. ResultsPatient and primary cadaver pancreas graft functional (insulinindependence) survival rates at 1 year by category and era were as follows: SPK, era 2 (n ϭ 214) versus eras 3 and 4 combined (n ϭ 212), 85% and 64% versus 92% and 79%, respectively; PAK, era 1 (n ϭ 36) versus 2 (n ϭ 61) versus 3 (n ϭ 84) versus 4 (n ϭ 92), 86% and 17%, 98% and 59%, 98% and 76%, and 98% and 81%, respectively; in PTA, era 1 (n ϭ 36) versus 2 (n ϭ 72) versus 3 (n ϭ 30) versus 4 (n ϭ 40), 77% and 31%, 99% and 50%, 90% and 67%, and 100% and 88%, respectively. In eras 3 and 4 combined for primary cadaver SPK transplants, pancreas graft survival rates were significantly higher with bladder drainage (n ϭ 136) than enteric drainage (n ϭ 70), 82% versus 74% at 1 year (P ϭ .03). Increasing recipient age had an adverse effect on outcome only in SPK recipients. Vascular disease was common (in eras 3 and 4, 27% of SPK recipients had a pretransplant myocardial infarction and 40% had a coronary artery bypass); those with no vascular disease had significantly higher patient and graft survival rates in the SPK and PAK categories. Living donor segmental pancreas transplants were associated with higher technically successful graft survival rates in each era, predominately solitary (PAK and PTA) in eras 1 and 2 and SPK in eras 3 and 4. Diabetic seconda...

show abstract

Section: Description Of Eras Eramentioning

confidence: 99%

Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution

Sutherland¹,

Gruessner²,

Dünn³

et al. 2001

Annals of Surgery

611

434

View full text Add to dashboard Cite

show abstract

“…There are varying reports on long-and short-term survival rates of diabetic recipients compared to those of ND [7,10,[12][13][14]. While Eckberg and Christensson [7] and Shaffer et al [13] reported similar rates, in the present study, pre-TDM had lower survival rates than ND.…”

Section: Discussionmentioning

confidence: 38%

Inferior Long-Term Outcome of Renal Transplantation in Patients with Diabetes mellitus

et al. 2002

View full text Add to dashboard Cite

Objective: To retrospectively review the long-term outcome of renal transplant in diabetics at Mubarak Al-Kabeer Hospital and Hamad Al-Essa Organ Transplant Center, Kuwait from 1983 to 1998. Methods: There were 631 renal transplant patients, comprising 79 (12.5%) patients with pretransplant diabetes mellitus (pre-TDM), 117 (18.5%) patients with post-transplant diabetes mellitus and 435 (69%) nondiabetics (ND). Subjects with post-transplant diabetes mellitus were excluded from the comparative analysis. Distribution of sex, source of donors and mode of immunosuppression were similar in pre-TDM and ND groups. Results: Fifty-three (67%) recipients in pre-TDM and 90 (20.5%) in the ND group (p < 0.01) were above 45 years of age. However, 26 (33.3%) pre-TDM and 345 (79.5%) ND were below age 45. Among those who died, coronary artery disease led to death in 36% of pre-TDM and 27% in ND. Hyperlipidemia requiring drug therapy was observed in 37% pre-TDM and 6% ND. The incidence of severe infections was nearly twice in pre-TDM over ND recipients (1.9 vs. 1.0 per patient, p < 0.001). Acute rejection episodes were more frequently seen in pre-TDM (43%) than ND (33%), however the difference was not statistically significant. The patient survivals at 1, 5, 10, 14 years were significantly lower in pre-TDM (84, 65, 58 and 58%, respectively) than in ND (97, 93, 86 and 82%, respectively). The major contributory factors were severe infections and coronary artery disease. The cumulative graft survival showed a similar pattern (52% in pre-TDM, 73% in ND at 10 years). However, when death is excluded, the 10-year pure graft survival probability was similar for the pre-TDM and ND groups (76% vs. 80%). Conclusion: Our study indicates poor patient survival in pre-TDM due to coronary artery disease and infections, whereas the pure long-term graft survival was equally good in pre-TDM and ND transplant recipients.

show abstract

“…One large-scale collaborative study re ported 1 -year graft survival rates of 69 and 58% for living related and cadaveric donors, respectively [7]. More re cently, Sutherland et al [8] reported patient and graft 2-year survival rales of 88 and 92%, respectively, in dia betic recipients as compared with 92 and 79% in nondia-bctics. As a result of such observations, renal transplanta tion is now commonly regarded as a treatment of choice for the patient with diabetic nephropathy [8], Such improvement in graft longevity has prompted investigation into the possible adverse effects that diabetes mellitus may exert upon renal function, particularly since it is known that laboratory animals with experimental dia betes develop nephropathy in normal kidneys received as transplants [9], In this regard.…”

Section: Discussionmentioning

confidence: 99%

“…In view of the improving graft survival rates being reported [8], it is reasonable to anticipate an increased incidence of this complication in transplanted diabetic patients with the obvious medical and economic conse quences.…”

Section: Discussionmentioning

confidence: 99%

De novo Diabetic Nephropathy with Functional Impairment in a Renal Allograft

Lf¹,

Aj²,

Cr³

et al. 1986

Am J Nephrol

View full text Add to dashboard Cite

Recurrence of diabetic nephropathy in the allograft of diabetics with end-stage renal disease who undergo renal transplantation has been reported. We report a case of a patient who underwent cadaveric renal transplantation for end-stage renal disease secondary to chronic glomerulonephritis 13 years ago. He developed steroid-induced, insulin-dependent diabetes mellitus 9 months after transplantation and florid nephrotic syndrome with progressive functional impairment due to biopsy-proven diabetic nephropathy 11 years later. This is, to our knowledge, the first report of de novo diabetic nephropathy in a renal allograft of a patient who was not a diabetic at the time of transplantation. It is suggested that histopathologic changes of diabetes mellitus cannot only recur in a renal allograft, but also can develop de novo and lead to functional impairment and ultimately affect graft survival. In view of increasing patient and graft survival in transplanted diabetic and non-diabetic patients, it is reasonable to anticipate an increased incidence of this complication.

show abstract

Improved Patient and Primary Renal Allograft Survival in Uremic Diabetic Recipients

Cited by 8 publications

References 0 publications

Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution

Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution

Inferior Long-Term Outcome of Renal Transplantation in Patients with Diabetes mellitus

De novo Diabetic Nephropathy with Functional Impairment in a Renal Allograft

Contact Info

Product

Resources

About